Achillion Pharmaceuticals, Inc. Reports HCV Pipeline Progress And Outlines 2014 HCV Milestones
NEW HAVEN, Conn., Jan. 13, 2014 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported progress on the Company's portfolio of proprietary compounds for the treatment of chronic hepatitis C (HCV) and outlined its 2014 milestones.
Help employers find you! Check out all the jobs and post your resume.